



Burden of Typhoid in **Malawi**

Malawi is a typhoid-endemic country, with a high burden of typhoid.

A large typhoid surveillance study called Strategic Typhoid Alliance across Africa and Asia (STRATAA) was conducted in Blantyre and estimated a rate of **444 typhoid cases per 100,000 people** per year.

The bacteria that causes typhoid, *S. Typhi*, was the primary cause of bloodstream infection in people with fever in the surveillance study.

Additionally, **children 5-9 years old had the highest typhoid incidence rate** of all age groups included in the study.¹

While typhoid is rarely fatal, the recovery is long and difficult. The disease steals time, money, and productivity from those infected and their families and is associated with numerous long-term complications.

Drug resistance has likely caused typhoid cases in Malawi to increase rapidly over the past years.^{2,3}



Data from Blantyre show that **multidrug-resistant (MDR) typhoid** strains became prominent in 2011.



Following the introduction of MDR strains in 2011, **typhoid became the predominant bloodstream infection among adults and children in Malawi**, with a 21% incidence of complications among children.²⁻⁴



The recent STRATAA study found **high rates of MDR typhoid in Malawi**. 92% of isolates were MDR.¹



All isolates from typhoid cases identified in a large Phase 3 typhoid conjugate vaccine efficacy study conducted in Malawi were MDR.⁴

Most typhoid cases in Malawi occur in children **younger than 15 years old.**¹



Photo: TyVAC/Madalits Mvula

The Government of Malawi prioritized child health and introduced typhoid conjugate vaccine (TCV) into the routine immunization program in 2023. More than 7 million children were vaccinated during the catch-up campaign and TCV is now available to all children at 9 months old.

Typhoid conjugate vaccines (TCVs) in Malawi

The World Health Organization (WHO) recommends the introduction of prequalified TCVs be prioritized in countries with a high burden of typhoid disease or a high burden of drug-resistant typhoid. Malawi introduced TCV into its routine childhood immunization program in 2023 with support from Gavi, the Vaccine Alliance. TCVs:



Are highly effective and safe for children as young as **6 months** of age;



Require a **single dose** to prevent 79-85% of typhoid cases in children;³



Offer strong protection for **at least 4 years**; and



Can be **co-administered with measles-rubella vaccine**.⁵



The Government of Malawi has **introduced TCV** into their routine immunization program.

Findings from an economic analysis predict that, even in the absence of a Gavi subsidy, a catch-up campaign with TCV could be cost-effective in Malawi.⁶



Let's Take on Typhoid in Malawi

- ✓ Typhoid is endemic in Malawi, with a **high rate** of typhoid cases per year.
- ✓ Malawi's burden of typhoid is most heavily borne by children **younger than 15** years of age.
- ✓ Data show **increasing rates of drug-resistant typhoid**, making cases more difficult to treat.
- ✓ **TCVs** are safe, effective, and WHO-recommended for routine immunization as part of a cost-effective, integrated approach to typhoid prevention and control alongside safe water, sanitation, and hygiene interventions.
- ✓ Malawi **introduced TCV** in 2023. TCV is available for all children 9 months of age.

1. Meiring JE, Shakya M, Khanam F, et al. Burden of enteric fever at three urban sites in Africa and Asia: A multicentre population-based study. *The Lancet Global Health*. 2021;9(12):E1688-1696.
2. Feasey NA, Gaskell K, Wong V, et al. Rapid emergence of multidrug resistant, H5H-lineage *Salmonella* Typhi in Blantyre, Malawi. *PLoS Neglected Tropical Diseases*. 2015;9(4):E0003748.
3. Feasey NA, Masesa C, Jassi C, et al. Three epidemics of invasive multidrug-resistant *Salmonella* bloodstream infection in Blantyre, Malawi, 1998-2014. *Clinical Infectious Diseases*. 2015;61(Suppl 4):S363-S371.
4. Patel PD, Patel P, Liang Y, et al. Safety and efficacy of a typhoid conjugate vaccine in Malawian children. *New England Journal of Medicine*. 2021;385(12):1104-1115.
5. Sirima SB, Ouedraogo A, Barry N, et al. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial. *International Journal of Infectious Diseases*. 2021;108:465-472.
6. Blicke J, Antillon M, Pieters Z, et al. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: A modelling study. *The Lancet Infectious Diseases*. 2019;19(7):728-739.